<DOC>
	<DOC>NCT00501566</DOC>
	<brief_summary>The primary objective is to determine the optimal dose or range of doses of SR121463B for the treatment of ascites when used concomitantly with a standard dose regimen of spironolactone and furosemide. The secondary objective is to determine the tolerability of different fixed doses of SR121463B over a 14 day treatment period in cirrhotic ascites.</brief_summary>
	<brief_title>Satavaptan Dose-Ranging Study in Normonatraemic Patients With Cirrhotic Ascites</brief_title>
	<detailed_description />
	<mesh_term>Liver Cirrhosis</mesh_term>
	<mesh_term>Ascites</mesh_term>
	<mesh_term>Satavaptan</mesh_term>
	<criteria>Cirrhosis of the liver confirmed by ultrasound, endoscopic examination or biochemical evidence Moderate or tense ascites Serum sodium of &gt;130 mmol/l. The above information is not intended to contain all considerations relevant to a patientâ€™s potential participation in a clinical trial.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2007</verification_date>
	<keyword>cirrhotic ascites</keyword>
</DOC>